Processes for generating engineered cells and compositions thereof

Patent metadata

Field	Value
Publication number	US-12516099-B2
Application number	US-201917267000-A
Country	US
Kind code	B2
Filing date	Aug 9, 2019
Priority date	Aug 9, 2018
Publication date	Jan 6, 2026
Grant date	Jan 6, 2026

Abstract

The present disclosure provides processes for genetically engineering T cells, such as primary CD4+ T cells and/or CD8+ T cells, for use in cell therapy that does not involve expanding the cells. In particular aspects, the provided processes successfully generate compositions of engineered T cells, such as containing populations of engineered T cells, that express a chimeric antigen receptor (CAR) within a shortened amount of time as compared to alternative engineering processes, such as processes that involve expanding the cells. In certain aspects, the provided processes successfully generate a composition of engineered T cells suitable for use in cell therapy within 4 days from when the process to stimulate or activate the cells is initiated. In some aspects, the resulting engineered cell compositions are composed of cell population that are less differentiated, less exhausted, and more potent than engineered T cell compositions generated by other means, such as by processes that involve expanding the cells. Also provided are compositions of T cells generated by the provided methods and their uses for treating subjects.

First claim

What is claimed:

1 . A method for producing a composition of engineered T cells, the method comprising:
(a) exposing an input composition comprising primary T cells with a stimulatory reagent under conditions to stimulate T cells, wherein the stimulatory reagent comprises (i) an anti-CD3 antibody or antigen-binding fragment thereof and (ii) an anti-CD28 antibody or an antigen-binding fragment thereof, each bound to a bead, thereby generating a stimulated population; (b) introducing into T cells of the stimulated population a viral vector comprising a heterologous polynucleotide encoding a recombinant protein, thereby generating a population of transformed T cells; (c) incubating the population of transformed T cells in a serum-free medium, thereby generating an incubated population of transformed T cells, wherein the serum-free medium comprises 50 IU/mL to 200 IU/mL recombinant IL-2, 50 IU/mL to 200 IU/mL recombinant IL-15, and 500 IU/mL to 1,000 IU/mL recombinant IL-7, and wherein the heterologous polynucleotide becomes integrated into the genome of T cells of the incubated population; (d) harvesting cells of the incubated population of transformed T cells, wherein the harvesting is carried out at a time between 48 and 120 hours, inclusive, after the exposing to the stimulatory reagent is initiated; and (e) formulating the harvested cells in a composition for cryopreservation, wherein the formulated composition is suitable for use as a cell therapy for administration to a subject.

2 . The method of claim 1 , wherein the incubating is carried out for up to 96 hours.

3 . The method of claim 1 , wherein the incubating is carried out for between 60 hours to 120 hours.

4 . The method of claim 1 , wherein the incubating is carried out under static conditions.

5 . The method of claim 1 , wherein one or both of the exposing in (a) and the introducing in (b) is carried out in the presence of one or more recombinant cytokines, wherein the one or more recombinant cytokines comprise recombinant IL-2, recombinant IL-7, and recombinant IL-15.

6 . The method of claim 5 , wherein one or both of the exposing in (a) and the introducing in (b) is carried out in the presence of recombinant IL-2, recombinant IL-7 and recombinant IL-15.

7 . The method of claim 1 , wherein one or both of the exposing in (a) and the introducing in (b) is carried out in a serum-free medium.

8 . The method of claim 7 , wherein the serum-free medium in which one or both of the exposing in (a) and the introducing in (b) is carried out comprises recombinant IL-2, recombinant IL-7, recombinant IL-15, or any combination thereof.

9 . The method of claim 7 , wherein the serum-free medium in which one or both of the exposing in (a) and the introducing in (b) is carried out comprises recombinant IL-2, recombinant IL-7 and recombinant IL-15.

10 . The method of claim 9 , wherein the serum-free medium in which one or both of the exposing in (a) and the introducing in (b) is carried out comprises
(a) 50 IU/mL to 200 IU/mL recombinant IL-2, (b) 500 IU/mL to 1000 IU/mL recombinant IL-7, and (c) 50 IU/mL to 200 IU/mL recombinant IL-15.

11 . The method of claim 1 , wherein the input composition comprises at least about 300×10 6 viable primary T cells.

12 . The method of claim 11 , wherein the incubating is carried out for up to 96 hours.

13 . The method of claim 11 , wherein the incubating is carried out for between 60 hours to 120 hours.

14 . The method of claim 1 , wherein at least about 80% of the cells in the input composition are CD3+ T cells or are CD4+ T cells and CD8+ T cells.

15 . The method of claim 1 , wherein the input composition comprises a ratio of between 1.5:1 and 2.0:1 CD4+ to CD8+ T cells.

16 . The method of claim 1 , wherein the input composition comprises a ratio of about 1:1 CD4+ to CD8+ T cells.

17 . The method of claim 1 , wherein the method comprises prior to the exposing to the stimulatory reagent, enriching CD3+ T cells or CD4+ T cells and CD8+ T cells from a biological sample to produce the input composition and wherein the biological sample:
comprises primary T cells obtained from a subject; comprises a whole blood sample, a buffy coat sample, a peripheral blood mononuclear cells (PBMC) sample, an unfractionated T cell sample, a lymphocyte sample, a white blood cell sample, an apheresis product, or a leukapheresis product; or is an apheresis or leukapheresis product that has been previously cryofrozen prior to the enriching.

18 . The method of claim 1 , wherein the incubated population of transformed T cells is harvested as an output composition in one or more containers, wherein the output composition comprises at least about 5×10 6 total cells.

19 . The method of claim 1 , wherein the introducing is carried out in the presence of a transduction adjuvant.

20 . The method of claim 1 , wherein the recombinant protein comprises a TCR or antigen-binding fragment thereof.

21 . The method of claim 1 , wherein the recombinant protein is a chimeric antigen receptor (CAR).

22 . The method of claim 1 , comprising during or subsequent to the incubation adding an agent to reduce the binding between the stimulatory reagent and the T cells.

23 . The method of claim 1 , wherein the bead is a magnetic bead particle.

24 . The method of claim 23 , comprising during or subsequent to the incubation adding an agent to reduce the binding between the stimulatory reagent and the T cells.

25 . The method of claim 1 , wherein:
the stimulatory reagent comprises a magnetic bead bound to the anti-CD3 antibody or antigen-binding fragment thereof and the anti-CD28 antibody or antigen-binding fragment thereof; the exposing and the introducing are carried out in the presence of serum free medium that includes recombinant IL-2, IL-7, and IL-15; the incubating is carried out for between 24 hours and 96 hours; and the harvesting is carried out at a time between 72 and 120 hours, inclusive, after the exposing to the stimulatory reagent is initiated.

26 . The method of claim 1 , the method further comprising adding a substance to the cells either subsequent to or during at least a portion of the incubating, wherein the substance terminates or lessens stimulation of the T cells by the stimulatory reagent.

27 . The method of claim 1 , wherein the serum-free medium comprises 0.5 mM to 5 mM of a dipeptide form of L-glutamine and 0.5 mM to 5 mM L-glutamine.

28 . A method for producing a composition comprising engineered T cells, the method comprising:
(a) stimulating a cell composition comprising CD4+ and CD8+ T cells obtained from a biological sample from a human subject, by exposing the cell composition to an anti-CD3 antibody or an antigen-binding fragment thereof and an anti-CD28 antibody or an antigen-binding fragment thereof, each bound to a bead, in a first serum-free medium, wherein the first serum-free medium comprises: (1) recombinant interleukin-2 (IL-2) at a concentration of 50 IU/mL to 200 IU/mL, (2) recombinant IL-7 at a concentration of 500 IU/mL to 1000 IU/mL; (3) recombinant IL-15 at a concentration of 50 IU/mL to 200 IU/mL, (4) a dipeptide form of L-glutamine at a concentration of 0.5 mM to 5 mM, and (5) L-glutamine at a concentration of 0.5 mM to 5 mM, thereby producing a population of stimulated T cells; (b) introducing a lentiviral ve

Assignees

• Juno Therapeutics Inc

Inventors

• Westoby Matthew
• Briggs Adrian Wrangham
• Kugler David G
• Germeroth Lothar
• Stemberger Christian
• Poltorak Mateusz Pawel
• Varun Divya
• Bashour Keenan
• Caspary Robert Guy
• Chan Calvin

Classifications

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K40/4215

  Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30 · CPC title

• A61K40/4211

  CD19 or B4 · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title